We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume |
---|---|---|---|---|---|
TBIO | Telesis Bio Inc | 4.75 | 2.43 | 104.74% | 3,000,074 |
NCNA | NuCana PLC | 3.80 | 0.75 | 24.59% | 2,088,083 |
ICG | Intchains Group Ltd | 10.28 | 1.87 | 22.24% | 4,097 |
LSB | LakeShore Biopharma Company Ltd | 0.90 | 0.13 | 16.88% | 3,052 |
MU | Micron Technology Inc | 109.72 | 13.95 | 14.57% | 16,792,063 |
AMLI | American Lithium Corporation | 0.53 | 0.06 | 12.77% | 72,824 |
GIFT | RDE Inc | 2.78 | 0.27 | 10.76% | 2,204 |
FBIO | Fortress Biotech Inc | 1.55 | 0.14 | 9.93% | 647,376 |
HOLO | MicroCloud Hologram Inc | 0.2619 | 0.0209 | 8.67% | 7,713,040 |
ASTI | Ascent Solar Technologies Inc | 2.45 | 0.195 | 8.65% | 1,889 |
ANIX | Anixa Biosciences Inc | 3.4099 | 0.2599 | 8.25% | 150 |
Pagaya Technologies LTD. (NASDAQ: PGY) (“Pagaya” or the “Company”), a global technology company delivering AI-driven product solutions for the financial ecosystem, today announced that its wholly owned subsidiary, Pagaya US Holding Company LLC (“Pagaya US”), intends to offer, subject to market and other conditions, $125 million aggregate principal amount of exchangeable senior notes due 2029 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Pagaya US also expects to grant the initial purchasers of the notes an option to ...
Announces focus on therapeutic approach; resulting in a faster and more cost-effective path to approval SAN JOSE, Calif., Sept. 24, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced its strategic plan for a Phase 2 study for its breast cancer vaccine. The Phase 1 trial is being conducted at Cleveland Clinic, funded by a grant from the U.S. Department of Defense.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvve-updates-shareholders-on-compliance-measures-302257834.html SOURCE Nuvve Holding Corp.
Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced significant new findings from its Phase 2 trial of LODER™ in patients with non-resectable locally advanced pancreatic cancer (LAPC) which bear the KRAS G12D or G12V mutation (approximately 70% of pancreatic cancer patients). Overall the updated analysis reveals a 56% objective response rate (ORR) in patients treated with LODER, with the ORR increasing to 67% in patients whose previously non-resectable tumors became resectable. This marks a significant step forward in potentially improving surgical outcomes for LAPC patients.
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 63,051.86 | -1,216.79 | -1.89% | 1.24T | 2,868,659,302 |
ETH | Ethereum | 2,571.85 | -81.20 | -3.06% | 309.32B | 1,491,488,893 |
USDT | Tether USD | 0.99974 | -0.00022 | -0.02% | 97.82B | 200,588,050 |
BNB | Binance Coin | 585.51 | -20.35 | -3.36% | 92.54B | 188,009,436 |
SOL | Solana | 147.57 | -5.18 | -3.39% | 65.31B | 1,000,059,825 |
XRP | Ripple | 0.5831 | -0.008 | -1.35% | 31.85B | 202,969,108 |
USDC | USD Coin | 0.9999 | -0.0001 | -0.01% | 28.07B | 695,105,254 |
STETH | stETH | 2,574.43 | -78.92 | -2.97% | 25.24B | 2,545,751 |
TONCOIN | Wrapped TON Coin | 5.79 | 0.178715 | 3.19% | 20.06B | 74,018,565 |
DOGE | Dogecoin | 0.10839 | -0.00134 | -1.22% | 15.53B | 160,644,742 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions